Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
IJPR-Iranian Journal of Pharmaceutical Research. 2016; 15 (1): 247-252
Dans Anglais | IMEMR | ID: emr-177555

Résumé

Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment


Sujets)
Humains , Femelle , Mâle , Adulte d'âge moyen , Tuberculose pulmonaire , Antituberculeux/effets indésirables , Effets secondaires indésirables des médicaments , Lésions hépatiques dues aux substances , Foie/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
Détails de la recherche